Safety of monoclonal antibodies for the treatment of multiple sclerosis

@article{McGinley2017SafetyOM,
  title={Safety of monoclonal antibodies for the treatment of multiple sclerosis},
  author={Marisa P McGinley and Brandon P Moss and Jeffrey A. Cohen},
  journal={Expert Opinion on Drug Safety},
  year={2017},
  volume={16},
  pages={100 - 89}
}
ABSTRACT Introduction: Monoclonal antibodies are a potent therapeutic approach for relapsing-remitting multiple sclerosis. This group of medications comprises diverse mechanisms of action resulting in both shared and unique adverse effects. Areas covered: The major trials and safety profiles of natalizumab, alemtuzumab, daclizumab, rituximab, and ocrelizumab are discussed. While each drug has a unique safety profile, one of the potential safety concerns for all of these drugs is infection… 
Adverse events and monitoring requirements associated with monoclonal antibody therapy in patients with multiple sclerosis
  • Y. Fragoso
  • Medicine
    Drugs & Therapy Perspectives
  • 2019
TLDR
The type and management of adverse events associated with MAb treatment in patients with MS are summarized, the importance of evidence-based knowledge for all neurologists involved in MS therapy is emphasized, and the need to be aware of their potential risks is emphasized.
[Highly active multiple sclerosis: options for monoclonal antibody therapy].
  • N. Khachanova
  • Medicine
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
  • 2019
TLDR
The review presents data on the effectiveness of three monoclonal antibody drugs - natalizumab, alemtuzumab and ocrelizumabs to help the physician make a balanced choice of a drug and therapy strategy.
[Highly active multiple sclerosis: options for monoclonal antibody therapy].
TLDR
The review presents data on the effectiveness of three monoclonal antibody drugs - natalizumab, alemtuzumab and ocrelizumabs to help the physician make a balanced choice of a drug and therapy strategy.
Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?
TLDR
This review provides an up-to-date review of both RCTs and real-world studies assessing the safety and efficacy profiles of recently developed disease-modifying drugs for relapsing remitting MS, including fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab and ocrelizumab.
Nogo-A Antibodies for Progressive Multiple Sclerosis
TLDR
Solid pre-clinical data suggest neutralization of the neurite outgrowth inhibitor Nogo-A as a potential new way to achieve both axonal and myelin repair and the potential of NogoA-antibodies as a therapy for progressive MS is elucidated.
HSV-2-encephalitis in a patient with multiple sclerosis treated with ocrelizumab
TLDR
The case of a 61-year-old man with secondary progressive multiple sclerosis, who suffered from HSV-2-encephalitis under treatment with ocrelizumab, which is regarded as a postictal condition.
Differential Effects of MS Therapeutics on B Cells—Implications for Their Use and Failure in AQP4-Positive NMOSD Patients
TLDR
It is concluded that the differential effect of MS drugs on B cells is one potential parameter determining the therapeutic efficacy or failure in antibody-dependent diseases like seropositive NMOSD.
New fungal infections associated with disease-modifying treatments in MS
TLDR
Physicians should be familiar with safety concerns and follow patients closely to rapidly identify existing or emerging issues in relapsing–remitting multiple sclerosis.
Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-Analysis
TLDR
High-quality evidence shows that alemtuzumab, natalizumab and ocrelizumAB present the highest efficacy among DMTs, and other meta-analyses are required regarding adverse events frequency, to better understand the safety of therapies.
B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders
TLDR
Current pathogenetic concepts in NMOSD are reviewed with a focus on the role of B cells and autoantibodies as major contributors to the propagation of these diseases.
...
1
2
3
...

References

SHOWING 1-10 OF 127 REFERENCES
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
TLDR
The alemtuzumab clinical development program used an active comparator, subcutaneous interferon beta-1a, to show that alemTuzumAB is a highly efficacious disease-modifying therapy, with benefits on relapses, disability outcomes, and freedom from clinical disease and magnetic resonance imaging activity.
Getting specific: monoclonal antibodies in multiple sclerosis
TLDR
Monoclonal antibodies that are already licensed to treat other diseases, such as cancer and autoimmune diseases, are being tested for the treatment of MS and novel targets are currently being investigated for MS.
Emerging injectable therapies for multiple sclerosis
TLDR
This Rapid Review, which summarises emerging injectable therapies for relapsing-remitting MS, and discusses pharmacological mechanisms, clinical trials, adverse events, and use in clinical practice, concludes that further clarification of purported mechanisms of action and continued surveillance will be essential to establish the safety and clinical efficacy of these drugs.
ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
TLDR
This study represents the first in-depth and longitudinal functional analysis of key immunological parameters in the periphery and the CNS compartment underlying the fundamental effects of alemtuzumab in MS patients, potentially identifying immune signatures associated with treatment response or the development of secondary autoimmunity.
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis
TLDR
Ofatumumab (up to 700 mg) given 2 weeks apart was not associated with any unexpected safety concerns and was well tolerated in patients with RRMS, and MRI data suggest a clinically meaningful effect of ofatumumrab for all doses studied.
A link between long-term natalizumab dosing in MS and PML
  • E. Major, A. Nath
  • Medicine
    Neurology: Neuroimmunology & Neuroinflammation
  • 2016
When an infectious serious adverse event is linked with a therapy for an underlying disease, it usually is seen in a few weeks or months, not years. This is not the case with the effective monoclonal
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis
TLDR
Rituximab add-on therapy was effective based upon blinded radiologic endpoints in this phase II study and b-cell–modulating therapy remains a potential option for treatment of patients with relapsing MS with an inadequate response to standard injectable therapies.
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
TLDR
The similarly pronounced effects of B-cell depletion with both ocrelizumab doses on MRI and relapse-related outcomes support a role for B-cells in disease pathogenesis and warrant further assessment in large, long-term trials.
Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
TLDR
Two patients treated with alemtuzumab for MS developing Listeria meningitis few days after the first infusion cycle are reported, indicating a serious, but treatable complication.
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
TLDR
Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures in 10 multiple sclerosis patients with incomplete response to IFN-beta therapy and high brain inflammatory and clinical disease activity.
...
1
2
3
4
5
...